DISEASE/CONDITION(S)

Alzheimer's disease (AD)

GUIDELINE CATEGORY

Assessment of Therapeutic Effectiveness

Management

Treatment

CLINICAL SPECIALTY

Family Practice

Geriatrics

Internal Medicine

Neurology

Pharmacology

Psychiatry

INTENDED USERS

Advanced Practice Nurses

Physician Assistants

Physicians

GUIDELINE OBJECTIVE(S)

* To provide an update review of the best quality evidence for the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine, and galantamine for mild to moderately-severe Alzheimer's disease (AD)

* To provide a review of the best quality evidence for the clinical effectiveness and cost-effectiveness of memantine for moderately-severe to severe AD